Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 2,752 Cr.
- Current Price ₹ 576
- High / Low ₹ 734 / 422
- Stock P/E
- Book Value ₹ 347
- Dividend Yield 0.00 %
- ROCE 4.91 %
- ROE -0.11 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.27% over past five years.
- Company has a low return on equity of -12.0% over last 3 years.
- Promoters have pledged 36.6% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | |
| 462 | 1,173 | 1,065 | 1,232 | 1,187 | 1,309 | 1,384 | 1,080 | 1,182 | |
| Operating Profit | 59 | 214 | 257 | 385 | 81 | 134 | -95 | 204 | 187 |
| OPM % | 11% | 15% | 19% | 24% | 6% | 9% | -7% | 16% | 14% |
| 2 | 12 | 27 | 28 | 14 | 22 | -184 | 9 | 0 | |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 106 | 115 | 94 |
| Depreciation | 34 | 83 | 94 | 108 | 112 | 111 | 103 | 99 | 100 |
| Profit before tax | 2 | 61 | 112 | 221 | -92 | -45 | -488 | -1 | -7 |
| Tax % | 0% | 3% | 0% | 0% | -36% | -50% | 16% | 0% | 0% |
| 2 | 59 | 112 | 221 | -59 | -22 | -567 | -1 | -7 | |
| EPS in Rs | 17.06 | 31.42 | 46.13 | -12.20 | -4.63 | -118.10 | -0.30 | -2.00 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| TTM: | -25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -18% |
| 3 Years: | 16% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -12% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 745 | 937 | 1,064 | 1,557 | 1,491 | 1,467 | 901 | 1,056 | 1,211 |
| 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 637 | |
| 414 | 456 | 339 | 397 | 373 | 379 | 398 | 333 | 384 | |
| Total Liabilities | 1,817 | 1,957 | 2,152 | 2,610 | 2,937 | 2,895 | 2,347 | 2,225 | 2,277 |
| 1,063 | 1,195 | 1,374 | 1,359 | 1,334 | 1,342 | 1,261 | 1,187 | 1,231 | |
| CWIP | 70 | 39 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 19 | 18 | 18 | 18 | 15 | 16 | 14 | 2 | 2 |
| 666 | 705 | 719 | 1,145 | 1,350 | 1,298 | 815 | 757 | 839 | |
| Total Assets | 1,817 | 1,957 | 2,152 | 2,610 | 2,937 | 2,895 | 2,347 | 2,225 | 2,277 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 50 | 166 | 242 | 154 | -242 | 156 | 111 | 213 | 153 | |
| -85 | -113 | -359 | -105 | -243 | -81 | -5 | -37 | -50 | |
| 67 | -23 | 97 | 92 | 334 | -113 | -107 | -180 | -103 | |
| Net Cash Flow | 32 | 30 | -20 | 142 | -151 | -38 | -0 | -5 | 0 |
| Free Cash Flow | 15 | 107 | -26 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/OP | 90% | 84% | 103% | 49% | -276% | 106% | -116% | 105% | 83% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 185 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 126 | 131 | 154 | 150 | 139 | 140 | 141 | 143 |
| Cash Conversion Cycle | 17 | 62 | 102 | 104 | 312 | 256 | 123 | 137 | 144 |
| Working Capital Days | -120 | -20 | -30 | 17 | 39 | 22 | -129 | -61 | -22 |
| ROCE % | 10% | 12% | 15% | -1% | 2% | -9% | 6% | 5% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| R&D Spend (charged to P&L) INR Crores |
|
||||||||
| Number of Countries Served count |
|||||||||
| Cumulative DMFs Filed count |
|||||||||
| Number of Permanent Employees count |
|||||||||
| Number of Products Commercialized count |
|||||||||
| Regulated Market Revenue Share % of total revenue |
|||||||||
| Total Reactor Capacity KL |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Approval Of The Reminder - Cum - Forfeiture Notice
1d - Final reminder for ₹131.25 first call and ₹112.50 second call due by 27 July 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Jun - Copy of newspaper advertisement regarding dispatch of notices to shareholders for the transfer of equity shares to the IEPF in respect of the unclaimed and …
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Transfer Of Equity Shares Of The Company To The IEPF
26 Jun - Solara notifies shareholders of possible IEPF transfer for FY2018-19 unclaimed dividend shares by 10/09/2026.
- Closure of Trading Window 25 Jun
-
Announcement under Regulation 30 (LODR)-Credit Rating
23 Jun - CRISIL upgraded Solara's Rs.791.2 crore bank facilities to BBB+/Stable and A2.
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025TranscriptPPTREC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPTREC
-
Jun 2024TranscriptPPTREC
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]